Nirmatrelvir
2628280-40-8
Nirmatrelvir (PF-07321332) is an orally bioavailable 3C-like protease (3CLPRO) inhibitor that is the subject of clinical trial NCT04756531. 3CLPRO is responsible for cleaving polyproteins 1a and 1ab of SARS-CoV-2.
Ritonavir
CAS 155213-67-5
*The following content is generated by AI and is for reference only.
Nirmatrelvir is a potent, oral antiviral medication developed specifically to treat coronavirus disease 2019 (COVID-19). Chemically known as the active ingredient in the combination drug Paxlovid, it functions as a selective inhibitor of the SARS-CoV-2 main protease, also referred to as 3CL protease or Mpro. This enzyme is essential for viral replication; by blocking its activity, Nirmatrelvir prevents the virus from processing its polyproteins into functional units, thereby halting the proliferation of the pathogen within host cells. The molecular formula of Nirmatrelvir is C25H37FN6O4S, and it carries the Chemical Abstracts Service (CAS) registry number 2183773-67-3. Its unique chemical structure features a nitrile group that covalently binds to the catalytic cysteine residue of the protease, ensuring high specificity and efficacy against the virus while minimizing off-target effects on human enzymes.
Clinically, Nirmatrelvir is administered orally in conjunction with ritonavir, which acts as a pharmacokinetic booster. Ritonavir inhibits the cytochrome P450 3A4 enzyme, slowing the metabolism of Nirmatrelvir and maintaining therapeutic plasma concentrations throughout the dosing period. The standard treatment regimen involves taking one tablet of Nirmatrelvir and two tablets of ritonavir twice daily for five days. It is indicated for adult patients with mild-to-moderate COVID-19 who are at high risk of progressing to severe disease, hospitalization, or death. Early administration, ideally within five days of symptom onset, is critical for maximizing clinical benefit. Extensive clinical trials have demonstrated that this combination significantly reduces the risk of hospitalization and mortality compared to placebo. While generally well-tolerated, healthcare providers must carefully review potential drug-drug interactions due to the strong inhibition of metabolic pathways by ritonavir. As a cornerstone of early outpatient management, Nirmatrelvir represents a significant advancement in the global fight against the pandemic, offering a convenient, non-invasive alternative to intravenous therapies.